41 results about "Casein kinases" patented technology

The invention discloses joint application of three types of monoclonal antibody-coupled immunomagnetic beads to sorting tumor cells and a method for sorting breast cancer tumor cells. The three types of monoclonal antibody-coupled immunomagnetic beads include anti-HLA-G (human leukocyte antigen-G) monoclonal antibody-coupled immunomagnetic beads, anti-EpCAM (epithelial cell adhesion molecule) monoclonal antibody-coupled immunomagnetic beads and anti-CK8 / 18 (casein kinase 8 / 18) monoclonal antibody-coupled immunomagnetic beads. The joint application and the method have the advantages that the three types of jointly applied antibody-coupled immunomagnetic beads are high in breast cancer tumor cell enrichment ratio and good in sensitivity and repeatability, and the relevant tumor cells can be detected; the three types of immunomagnetic beads (the anti-EpCAM immunomagnetic beads, the anti-HLA-G immunomagnetic beads and the anti-CK8 / 18 immunomagnetic beads) are jointly applied to enriching the tumor cells, so that the circulating tumor cell coverage rate can be increased to the greatest extent, the enrichment ratio can reach 80%, and a technology is international pioneer; the tumor cell enrichment specificity and sensitivity can be particularly guaranteed owing to usage of the anti-HLA-G monoclonal antibody-coupled immunomagnetic beads.

The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.

Disclosed are methods related to label-free biosensor cellular assays to classify multienzyme complex modulators in live cells. Disclosed are also methods related to the identification of purinosome disrupting Casein Kinase II (CK2) inhibitors, and methods related to the use of purinosome disrupting CK2 inhibitors as therapeutic agents for modulating CK2 activity and purine synthesis pathway, and for improving prevention and treatment of CK2 associated cancers, viral infection and inflammation conditions.

The present invention relates to compositions and methods useful in treating diseases and disorders related to protein kinases. In particular, the present invention relates to compositions and methods useful for targeting protein kinases related to mitogen activated protein kinase (MAPK) pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and / or casein kinase (CK) pathways (e.g., CK1δ, and upstream and downstream protein kinases), and diseases and disorders related to MAPK pathways (e.g., p38 MAPK, JNK, ERK, and upstream and downstream protein kinases) and / or CK pathways (e.g., CK1δ, and upstream and downstream protein kinases).

The present invention discloses and claims compounds of formula (I)as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.

The invention relates to peptides including DEDE(SSD)nDEG indicated by SEQ NO. 1, RRRDEDE(SSD)nDEG indicated by SEQ No. 2, RRRGDEDE(SSD)nDEG indicated by SEQ No. 3, and LKKLKKLDEDE(SSD)nDEG indicated by SEQ NO. 4, wherein n is an integer from 2 to 20. The invention also relates to phosphorylating these peptides at multiple amino acid sites by employing casein kinases. These phosphorylated peptides may be used in various applications such as forming mineralized collagen fibrils and biomimetic composites for use in tissue repair and regeneration.

This invention is related to the Molecular Pharmacology field and especially to the development of peptides useful for treating epithelial tumors and mainly those associated to oncogenic types of HPVs. The main objective of this invention is to identify peptides whose structure permits to block the Casein Kinase II (CKII) phosphorylation domain by direct interaction with such a site. In the present invention it is shown eleven cyclic peptides with different aminoacid sequences which inhibit the CKII phosphorylation in vitro, exhibit cytotoxicity on HPV-16 transformed cells (CaSki) and also increase the sensitivity of these cells to the cytostatic effect of interferon (IFN). Furthermore, the invention relates to the use of these peptides conjugated or fused to other peptides and chemical compounds which penetrates into cells as well as with the use of both peptide and chemical mimetic molecules.

The invention relates to chemical compounds which are obtained by means of in silico molecular modelling and which have a structure that can be used to block phosphorylation by interacting said compounds with the phosphorylation domain or the environment thereof in the substrates of the Casein Kinase II enzyme. The invention also relates to pharmaceutical compositions that contain said compounds and to the use thereof in the preparation of medicaments for the treatment of diseases associated with neoplastic processes.

A transgenic plant transformed by a casein kinase Stress-Related Polypeptide (CKSRP) coding nucleic acid, wherein expression of the nucleic acid sequence in the plant results in increased tolerance to environmental stress as compared to a wild type variety of the plant. Also provided are agricultural products, including seeds, produced by the transgenic plants. Also provided are isolated CKSRPs, and isolated nucleic acid coding CKSRPs, and vectors and host cells containing the latter.

The invention discloses corn casein kinase 2CK2[alpha]2 and application of a coding gene of the corn casein kinase 2CK2[alpha]2 based on high-temperature stress response, and aims to solve the technical problem that high-temperature-resistant gene resources and germplasm resources of corn are deficient at present. Based on the discovery that a corn casein kinase 2[alpha] subunit can respond to high temperature stress, overexpression vectors OE-ZmCK2[alpha]2 and pFGC5941-ZmCK2[alpha]2 overexpression vectors are constructed, ZmCK2[alpha]2 overexpression homozygous strains are obtained by using a corn genetic transformation technology, and strains with high expression quantity are screened out by using qRT-PCR (quantitative reverse transcription-polymerase chain reaction) detection and are used as breeding materials for breeding high-temperature-resistant corn varieties / lines. The invention determines that the corn casein kinase 2[alpha] subunit can respond to high-temperature stress, and preliminarily analyzes the action mechanism of the corn casein kinase 2[alpha] subunit under high-temperature stress, thereby being beneficial to understanding the heat-resistant mechanism of corn, and providing important gene resources and related germplasm resources for cultivating high-temperature-resistant corn varieties.

The present invention relates to methods with 3-arylthioindole-2-carboxamides, 5-substituted-3-arylthioindole-2-carboxamides and related analogues for treating a patient suffering from diseases or disorders of the central nervous system associated with the disturbance of the human circadian clock that are ameliorated by inhibition of casein kinase Ie activity such as , for example, mood disorders including major depressive disorder, bipolar I disorder and bipolar II disorder, and sleep disorders including circadian rhythm sleep disorders such as, for example, shift work sleep disorder, jet lag syndrome, advanced sleep phase syndrome and delayed sleep phase syndrome.

The invention relates to the technical field of biomedicines, and particularly relates to application of complete sequence protein of a human-derived ribosomal protein L22 (RPL22) in anti-cancer anti-tumor medicines. For the complete sequence protein of recombinant human-derived RPL22 in medicines for treating non-small cell lung cancer or anti-tumor medicines, the sequence of the RPL22 is as shown in a sequence 1. The recombinant human-derived RPL22 can be used as an endogenous casein kinase inhibitor to achieve the anti-cancer activity, and has an effect of individually inhibiting cancer cell activity in the field of non-small cell lung cancer inhibition. The protein is a human own endogenous protein, has good biological safety, and can be combined with other anti-cancer medicines on the premise that relatively strong anti-cancer activity is ensured so as to reduce dosage of other anti-cancer medicines and toxic and side effects of other anti-cancer medicines.

There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1δ and casein kinase 1ε. In addition, the present inhibitor inhibits casein kinase 1δ and casein kinase 1ε, and thus there is also provided a pharmaceutical agent useful for the treatment and / or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1δ or casein kinase 1ε is associated. There is further provided a pharmaceutical agent useful for the treatment of, particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. An inhibitor of casein kinase 1δ and casein kinase 1ε comprising, as an active ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof:wherein X represents a halogen atom which is fluorine, chlorine, bromine or iodine.

Provided are methods and compositions for treating an individual who has a medulloblastoma. Methods for treating an individual who has a medulloblastoma tumor can include a step of administering to the individual, at a dose sufficient to reduce the size and / or growth rate of the medulloblastoma tumor, a composition that includes a casein kinase II (CK2) inhibitor (e.g., a CK2-selective inhibitor such as CX-4945). In some cases, the medulloblastoma tumor is a hedgehog-dependent medulloblastoma tumor. In some cases, the medulloblastoma tumor is a hedgehog-independent medulloblastoma tumor. In some cases, the medulloblastoma tumor is smoothened inhibitor-resistant (SMO inhibitor-resistant). In some cases, the medulloblastoma is resistant to treatment with 4,5,6,7-tetrabromo-2H-benzotriazole (TBB). In some cases, the dose is sufficient to cause long term regression of the medulloblastoma tumor, and in some cases, the dose is sufficient to increase the chance of survival of the individual.